These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31685858)

  • 1. Therapeutic effects of methylphenidate for attention-deficit/hyperactivity disorder in children with borderline intellectual functioning or intellectual disability: A systematic review and meta-analysis.
    Sun CK; Tseng PT; Wu CK; Li DJ; Chen TY; Stubbs B; Carvalho AF; Chen YW; Lin PY; Cheng YS; Wu MK
    Sci Rep; 2019 Nov; 9(1):15908. PubMed ID: 31685858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities: A systematic review.
    Tarrant N; Roy M; Deb S; Odedra S; Retzer A; Roy A
    Res Dev Disabil; 2018 Dec; 83():217-232. PubMed ID: 30266025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
    Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
    J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.
    Storebø OJ; Krogh HB; Ramstad E; Moreira-Maia CR; Holmskov M; Skoog M; Nilausen TD; Magnusson FL; Zwi M; Gillies D; Rosendal S; Groth C; Rasmussen KB; Gauci D; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
    BMJ; 2015 Nov; 351():h5203. PubMed ID: 26608309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
    Liu Q; Zhang H; Fang Q; Qin L
    J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH.
    Liu YC; Chen VC; Yang YH; Chen YL; Gossop M
    Epidemiol Psychiatr Sci; 2021 Feb; 30():e14. PubMed ID: 33583471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amfetamine for attention deficit hyperactivity disorder in people with intellectual disabilities.
    Thomson A; Maltezos S; Paliokosta E; Xenitidis K
    Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD007009. PubMed ID: 19160313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses.
    Krogh HB; Storebø OJ; Faltinsen E; Todorovac A; Ydedahl-Jensen E; Magnusson FL; Holmskov M; Gerner T; Gluud C; Simonsen E
    BMJ Open; 2019 Mar; 9(3):e026478. PubMed ID: 30928951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.
    Castells X; Cunill R; Capellà D
    Eur J Clin Pharmacol; 2013 Mar; 69(3):347-56. PubMed ID: 22983311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression.
    Liang EF; Lim SZ; Tam WW; Ho CS; Zhang MW; McIntyre RS; Ho RC
    Int J Environ Res Public Health; 2018 Aug; 15(8):. PubMed ID: 30127314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B
    J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate dependency revisited: understanding the effects of methylphenidate in children with attention deficit hyperactivity disorder.
    Teicher MH; Polcari A; Anderson CM; Andersen SL; Lowen SB; Navalta CP
    J Child Adolesc Psychopharmacol; 2003; 13(1):41-51. PubMed ID: 12804125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.